Zealand Pharma A/S is a Denmark-based biotechnology company specializing in the discovery and development of peptide-based medicines for metabolic and gastrointestinal diseases. Its research focuses on engineered hormone analogs and other peptide therapeutics addressing obesity, type 2 diabetes, rare endocrine disorders, and related cardiometabolic conditions.
The company advances a pipeline from preclinical to late-stage clinical programs and has a track record of originating approved products via partners, including the GLP-1 receptor agonist lixisenatide and the glucagon analog dasiglucagon. Zealand Pharma combines in-house peptide design and formulation expertise with clinical development and strategic collaborations to progress candidates and, where appropriate, out-license commercialization to larger pharmaceutical companies.
